# Plain Language Summary: Food and Drug Amendments of 2022

This bill is essentially a renewal and update of how the FDA (Food and Drug Administration) funds its work reviewing and approving new medications, medical devices, and other health products. Think of it like a user fee system—companies that want to sell drugs or medical devices pay fees to the FDA, and that money goes directly toward speeding up the review process for those products.

The bill extends and modifies four main fee programs. First, prescription drug companies pay fees when they submit new drugs for approval, and this money helps the FDA review applications faster. Second, medical device manufacturers pay similar fees for their products. Third, generic drug makers (companies that produce cheaper copies of existing drugs after patents expire) pay fees to help the FDA review their applications more quickly. Fourth, companies making biosimilar products—which are like generic versions of complex biological drugs—also contribute fees. All of these fees are supposed to be used specifically to speed up the approval process, not for general FDA operations.

Beyond the fee structure, the bill tackles several other healthcare issues. It requires drug companies to report their plans for including diverse populations in clinical trials—meaning they need to show they're testing drugs on people of different races, ages, and backgrounds to ensure medications work fairly for everyone. The bill also pushes for more transparency about generic drug applications so people can understand why some cheaper drug alternatives take longer to reach the market. Additionally, it includes provisions to improve FDA inspections of drug manufacturing facilities, both domestic and foreign, to catch safety problems earlier.

The bill also encourages research into new areas like treatments for rare diseases, alternatives to animal testing, and advanced manufacturing technologies. It includes measures to help ensure that accelerated approval drugs (those approved quickly for serious conditions) actually deliver the promised benefits through follow-up studies. Overall, this is a comprehensive update to how the FDA operates and funds itself, with the goal of getting safe, effective medications and devices to patients faster while ensuring they work well for all populations.

Food and Drug Amendments of 2022

Eshoo, Anna G.

Food and Drug Amendments of 2022 This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars. The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials. In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.